BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29167279)

  • 1. Height, Obesity, and the Risk of
    Graff RE; Ahearn TU; Pettersson A; Ebot EM; Gerke T; Penney KL; Wilson KM; Markt SC; Pernar CH; Gonzalez-Feliciano AG; Song M; Lis RT; Schmidt DR; Vander Heiden MG; Fiorentino M; Giovannucci EL; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):193-200. PubMed ID: 29167279
    [No Abstract]   [Full Text] [Related]  

  • 2. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.
    Pettersson A; Lis RT; Meisner A; Flavin R; Stack EC; Fiorentino M; Finn S; Graff RE; Penney KL; Rider JR; Nuttall EJ; Martin NE; Sesso HD; Pollak M; Stampfer MJ; Kantoff PW; Giovannucci EL; Loda M; Mucci LA
    J Natl Cancer Inst; 2013 Dec; 105(24):1881-90. PubMed ID: 24292212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
    Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Study of Aspirin Use and Prostate Cancer Risk by
    Stopsack KH; Gonzalez-Feliciano AG; Peisch SF; Downer MK; Gage RA; Finn S; Lis RT; Graff RE; Pettersson A; Pernar CH; Loda M; Kantoff PW; Ahearn TU; Mucci LA;
    Cancer Epidemiol Biomarkers Prev; 2018 Oct; 27(10):1231-1233. PubMed ID: 30108097
    [No Abstract]   [Full Text] [Related]  

  • 5. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
    Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
    Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.
    Graff RE; Pettersson A; Lis RT; Ahearn TU; Markt SC; Wilson KM; Rider JR; Fiorentino M; Finn S; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Mucci LA
    Am J Clin Nutr; 2016 Mar; 103(3):851-60. PubMed ID: 26817504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
    Graff RE; Pettersson A; Lis RT; DuPre N; Jordahl KM; Nuttall E; Rider JR; Fiorentino M; Sesso HD; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Nguyen PL; Sweeney CJ; Mucci LA;
    Prostate; 2015 Jun; 75(9):897-906. PubMed ID: 25728532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
    Graff RE; Judson G; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
    Prostate; 2017 May; 77(6):647-653. PubMed ID: 28102015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
    Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
    Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.
    Penney KL; Pettersson A; Shui IM; Graff RE; Kraft P; Lis RT; Sesso HD; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2016 May; 25(5):745-9. PubMed ID: 26941365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 16. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
    Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA
    Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.